This week, Jeremy provides an update on the fight for approval of AMX0035, including an extended review period at the FDA and how new data and approval in Canada puts more pressure on the FDA to act quickly. He also talks to Dr. David Vequist, director of the Center for Medical Tourism Research at the University of the Incarnate Word, about the history of medical and pharmaceutical tourism around the world.
Learn more about the Center for Medical Tourism Research at https://my.uiw.edu/medical-tourism/index.html
To email the FDA and urge them to approve AMX0035 quickly, go to als.org/fda
Read more about the potential impact on FDA delay at https://www.wsj.com/articles/a-lot-to-figure-out-als-patients-weigh-travel-to-canada-to-get-drug-for-deadly-illness-11655906422?mod=hp_lista_pos2
To read the letter signed by 38 ALS clinical experts urging approval of AMX0035, go to https://www.als.org/stories-news/several-dozen-prominent-als-clinicians-call-fda-approve-amx0035